Janux Therapeutics Inc
Veridion Score
Composite trend over time
Why is JANX moving today?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for JANX.
JANX insider activity
Janux Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$875K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | 2026-06-02 | Doyle Janeen Noel | Insider | sell | $14.03 | 4,059 | 75,941 | $57K | SEC Form 4 |
| 2026-05-13 | 2026-05-11 | Dobek Maria | Insider | sell | $14.17 | 2,038 | 32,270 | $29K | SEC Form 4 |
| 2026-01-02 | 2026-01-02 | McIver Zachariah | Insider | sell | $13.73 | 2,714 | 23,286 | $37K | SEC Form 4 |
| 2026-01-02 | 2026-01-02 | Dobek Maria | Insider | sell | $13.73 | 1,462 | 15,373 | $20K | SEC Form 4 |
| 2026-01-02 | 2026-01-02 | DiRaimondo Thomas | Insider | sell | $13.73 | 2,505 | 124,425 | $34K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 11 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moJANX contract awards, year to date.
Public federal awards linked to this ticker.
JANX lobbying filings, year to date.
Registered lobbying filings matched to Janux Therapeutics Inc.